{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T04:48:34Z","timestamp":1788929314235,"version":"build-2803163510"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016545","name":"Roche Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016545","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["valuehealthregionalissues.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health Regional Issues"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.vhri.2026.101588","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T17:01:04Z","timestamp":1772038864000},"page":"101588","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Cost-Effectiveness of N-terminal Pro B-type Natriuretic Peptide for Evaluation and Management of People With Type 2 Diabetes in the Perspective of Brazilian Private Healthcare System"],"prefix":"10.1016","volume":"55","author":[{"given":"Guilherme","family":"Lemos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Neveux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"James L.","family":"Januzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodica","family":"Pop-Busui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus Vinicius","family":"Bolivar Malachias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.vhri.2026.101588_bib1","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1007\/s00125-023-06068-2","article-title":"Epidemiology of heart failure in diabetes: a disease in disguise","volume":"67","author":"Hoek","year":"2024","journal-title":"Diabetologia"},{"issue":"5","key":"10.1016\/j.vhri.2026.101588_bib2","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1002\/ehf2.12782","article-title":"Diabetes mellitus and risk of new-onset and recurrent heart failure: a systematic review and meta-analysis","volume":"7","author":"Kodama","year":"2020","journal-title":"ESC Hear Fail"},{"issue":"2","key":"10.1016\/j.vhri.2026.101588_bib3","first-page":"222","article-title":"A 10-year trend analysis of heart failure in the less developed Brazil","volume":"114","author":"Fernandes","year":"2020","journal-title":"Arq Bras Cardiol"},{"issue":"6","key":"10.1016\/j.vhri.2026.101588_bib4","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1093\/eurheartj\/ehaa1012","article-title":"Heart failure drug treatment: the fantastic four","volume":"42","author":"Bauersachs","year":"2021","journal-title":"Eur Heart J"},{"issue":"15","key":"10.1016\/j.vhri.2026.101588_bib5","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.jacc.2023.12.024","article-title":"ACC expert consensus decision pathway for treatment of heart failure with reduced ejection fraction","volume":"83","author":"Maddox","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.vhri.2026.101588_bib6","doi-asserted-by":"crossref","first-page":"e722","DOI":"10.1161\/CIR.0000000000001040","article-title":"Comprehensive management of cardiovascular risk factors for adults with type 2 diabetes: a scientific statement from the American Heart Association","volume":"145","author":"Joseph","year":"2022","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.vhri.2026.101588_bib7","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.cardfail.2023.08.014","article-title":"In-hospital management and long-term clinical outcomes and adherence in patients with acute decompensated heart failure: primary results of the first Brazilian registry of heart failure (BREATHE)","volume":"30","author":"De Albuquerque","year":"2024","journal-title":"J Card Fail"},{"issue":"Suppl 1","key":"10.1016\/j.vhri.2026.101588_bib8","first-page":"S179","article-title":"Cardiovascular disease and risk management: standards of care in Diabetes-2024","volume":"47","year":"2024","journal-title":"Diabetes Care"},{"issue":"15","key":"10.1016\/j.vhri.2026.101588_bib9","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.jacc.2013.05.069","article-title":"Pontiac (NT-proBNP Selected PreventiOn of cardiac eveNts in a populaTion of dIabetic patients without A history of Cardiac disease)","volume":"62","author":"Huelsmann","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.vhri.2026.101588_bib11","article-title":"Preval\u00eancia e tend\u00eancia temporal do diabetes autorreferido nas capitais dos estados brasileiros e do Distrito Federal, de 2010 a 2021","volume":"17","author":"Kluthcovsky","year":"2024","journal-title":"Contrib LAS Cienc Soc"},{"issue":"2","key":"10.1016\/j.vhri.2026.101588_bib12","doi-asserted-by":"crossref","first-page":"69","DOI":"10.37745\/bjmas.2022.0475","article-title":"Healthcare in Brazil: an overview","volume":"5","author":"Pan","year":"2024","journal-title":"Br J Multidiscip Adv Stud"},{"issue":"1","key":"10.1016\/j.vhri.2026.101588_bib13","article-title":"Performance of contemporary cardiovascular risk stratification scores in Brazil: an evaluation in the ELSA-Brasil study","volume":"11","author":"Camargos","year":"2024","journal-title":"Open Heart"},{"issue":"1","key":"10.1016\/j.vhri.2026.101588_bib14","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12933-021-01221-w","article-title":"Performance of the recommended ESC\/EASD cardiovascular risk stratification model in comparison to SCORE and NT-proBNP as a single biomarker for risk prediction in type 2 diabetes mellitus","volume":"20","author":"Prausm\u00fcller","year":"2021","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"10.1016\/j.vhri.2026.101588_bib15","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13098-021-00775-9","article-title":"Contemporary (2019) prevalence of cardiovascular disease in adults with type 2 diabetes in Brazil: the cross-sectional CAPTURE study","volume":"14","author":"Vencio","year":"2022","journal-title":"Diabetol Metab Syndr"},{"key":"10.1016\/j.vhri.2026.101588_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fcdhc.2022.934629","article-title":"BrazIliaN Type 1 & 2 DiabetEs Disease Registry (BINDER): longitudinal, real-world study of diabetes mellitus control in Brazil","volume":"3","author":"de Almeida-Pititto","year":"2022","journal-title":"Front Clin Diabetes Health"},{"issue":"21","key":"10.1016\/j.vhri.2026.101588_bib17","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMc1712572","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.vhri.2026.101588_bib18","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1161\/CIRCULATIONAHA.117.032038","article-title":"Canagliflozin for primary and secondary prevention of cardiovascular events","volume":"137","author":"Mahaffey","year":"2018","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.vhri.2026.101588_bib19","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jchf.2020.10.013","article-title":"Biomarker-based risk prediction of incident heart failure in pre-diabetes and diabetes","volume":"9","author":"Pandey","year":"2021","journal-title":"JACC Hear Fail"},{"key":"10.1016\/j.vhri.2026.101588_bib20","series-title":"PPP Conversion Factor, Brazil [Data set]","year":"2023"},{"issue":"4","key":"10.1016\/j.vhri.2026.101588_bib22","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1590\/S1516-93322006000400013","article-title":"Ades\u00e3o ao tratamento medicamentoso em pacientes com doen\u00e7as gastrintestinais cr\u00f4nicas acompanhados no ambulat\u00f3rio de um hospital universitario","volume":"42","author":"Dewulf","year":"2006","journal-title":"Rev Bras Cienc Farm"},{"key":"10.1016\/j.vhri.2026.101588_bib23","series-title":"Secretaria de ci\u00eancia, tecnologia, inova\u00e7\u00e3o e insumos Estrat\u00e9gicos em sa\u00fade departamento de gest\u00e3o e incorpora\u00e7\u00e3o de tecnologias em sa\u00fade. O uso de limiares de custo-efetividade nas decis\u00f5es em sa\u00fade. Brasilia","year":"2022"},{"issue":"3","key":"10.1016\/j.vhri.2026.101588_bib24","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.cardfail.2021.12.017","article-title":"Economic issues in heart failure in the United States","volume":"28","author":"Heidenreich","year":"2022","journal-title":"J Card Fail"},{"issue":"6","key":"10.1016\/j.vhri.2026.101588_bib25","first-page":"433","article-title":"I Brazilian registry of heart failure - clinical aspects, care quality and hospitalization outcomes","volume":"104","author":"Albuquerque DC de","year":"2015","journal-title":"Arq Bras Cardiol"},{"issue":"4","key":"10.1016\/j.vhri.2026.101588_bib26","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1093\/ije\/dyab104","article-title":"Data resource profile: surveillance system of risk and protective factors for chronic diseases by telephone survey for adults in Brazil (Vigitel)","volume":"50","author":"da Silva","year":"2021","journal-title":"Int J Epidemiol"}],"container-title":["Value in Health Regional Issues"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109926000026?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109926000026?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T11:22:33Z","timestamp":1788434553000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212109926000026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":24,"alternative-id":["S2212109926000026"],"URL":"https:\/\/doi.org\/10.1016\/j.vhri.2026.101588","relation":{},"ISSN":["2212-1099"],"issn-type":[{"value":"2212-1099","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Effectiveness of N-terminal Pro B-type Natriuretic Peptide for Evaluation and Management of People With Type 2 Diabetes in the Perspective of Brazilian Private Healthcare System","name":"articletitle","label":"Article Title"},{"value":"Value in Health Regional Issues","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vhri.2026.101588","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of International Society for Pharmacoeconomics and Outcomes Research, Inc.","name":"copyright","label":"Copyright"}],"article-number":"101588"}}